All In Biotech

Drug Trial Radar · NCT07776210

Study of d-MAPPS™ Ophthalmic Solution in Adults With Chronic Ocular Graft-Versus-Host Disease (oGVHD)

A Randomized, Double-Masked, Vehicle-Controlled, Adequate and Well-Controlled Pivotal Study With Co-Primary Endpoints to Evaluate the Safety and Efficacy of d-MAPPS™ Ophthalmic Solution in Subjects With Chronic Ocular Graft-Versus-Host Disease (oGVHD)

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Title says "pivotal". This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Sep 8, 2026

Primary completion

Mar 31, 2027

Study completion Jun 30, 2027

Sponsor

Sponsor type
Industry
First posted
Aug 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase III, multicenter, randomized, double-masked, vehicle-controlled, parallel-group clinical trial designed to evaluate the efficacy, safety, and tolerability of d-MAPPS™ Ophthalmic Solution in adult subjects with chronic ocular graft-versus-host disease (oGVHD). Eligible subjects will receive masked study treatment for 90 days, with the primary efficacy assessment performed at the Day 90 study visit.

Conditions

  • oGVHD
  • Ocular Graft Versus Host Disease

Interventions

  • d-MAPPS™ Ophthalmic SolutionBiological

    Sterile, preservative-free ophthalmic solution administered as two drops into each eye four times daily for 90 consecutive days.

  • Matching vehicle controlBiological

    Matching vehicle control supplied in identical masked containers and administered as two drops into each eye four times daily for 90 consecutive days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to Day 90 in Modified Oxford Corneal Staining ScoreTime frame: Baseline to Day 90 (±5 days)
  2. Change From Baseline to Day 90 in Ocular Surface Disease Index (OSDI) Total ScoreTime frame: Baseline to Day 90 (±5 days)

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Beverly Hills Institute of Ophthalmology

    Beverly Hills, California · Recruiting

  • Beverly Hills Optometry

    Beverly Hills, California · Recruiting

  • Regenerative Ocular Immunobiologics, LLC.

    Palm Harbor, Florida · Not yet recruiting

  • Eyewell, LLC.

    Boston, Massachusetts · Recruiting

  • BostonSight

    Boston, Massachusetts · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.